{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:34:13Z","timestamp":1790721253254,"version":"4.1.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006423","name":"Food Allergy Research and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>With the recent FDA approval of the anti-IgE biologic, omalizumab, in 2024 for the treatment of food allergy, it is critical to consider the advantages and disadvantages of anti-IgE and allergen-specific immunotherapies (AITs) to help determine optimal patient care. Several AITs have been studied for food allergy, including oral (OIT), sublingual (SLIT), and epicutaneous immunotherapy (EPIT) with varying degrees of safety and efficacy. There are obvious advantages of treating food allergies with omalizumab, including less frequent administration (every 2 or 4 weeks) compared to the daily dosing of AITs, treating multiple food allergies with one medication, and the potential benefit for comorbid asthma and environmental allergies. However, disadvantages of omalizumab include the requirement for lifelong treatment of a costly biologic that will not induce immunologic tolerance. On the other hand, AITs have been shown to effectively induce desensitization in most individuals and can lead to long-term tolerance or remission in a subset of patients. In this review, we will discuss the pros and cons of omalizumab and AITs and the potential benefit of combining both approaches in young children to achieve immediate increases in reaction threshold while also inducing tolerogenic immunologic responses.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1617153","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:10:44Z","timestamp":1753157444000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons"],"prefix":"10.3389","volume":"16","author":[{"given":"Michael D.","family":"Kulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Krempski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.","family":"Smeekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam9171","article-title":"A phenotypically and functionally distinct human T(H)2 cell subpopulation is associated with allergic disorders","volume":"9","author":"Wambre","year":"2017","journal-title":"Sci Transl Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw6433","article-title":"Identification of a T follicular helper cell subset that drives anaphylactic IgE","volume":"365","author":"Gowthaman","year":"2019","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2500\/jfa.2024.6.240003","article-title":"IgE and non-IgE food allergy: A review of immunological mechanisms","volume":"6","author":"Bellanti","year":"2024","journal-title":"J Food Allergy"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14487","article-title":"Mast cell versus basophil activation test in allergy: Current status","volume":"54","author":"Ebo","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.02.016","article-title":"Social determinants and quality of life in food allergy management and treatment","volume":"13","author":"Protudjer","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e185630","DOI":"10.1001\/jamanetworkopen.2018.5630","article-title":"Prevalence and severity of food allergies among US adults","volume":"2","author":"Gupta","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90080-L","article-title":"Treatment of peanut allergy with rush immunotherapy","volume":"90","author":"Oppenheimer","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)80006-1","article-title":"Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract","volume":"99","author":"Nelson","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000001058","article-title":"New approaches in childhood IgE-mediated food allergy treatment","volume":"25","author":"Gurel","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jaci.2015.04.029","article-title":"Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy","volume":"136","author":"Wang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000736","article-title":"Omalizumab as an adjuvant in food allergen immunotherapy","volume":"21","author":"Dantzer","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1409342","article-title":"Omalizumab for the reduction of allergic reactions to foods: a narrative review","volume":"5","author":"Ghouri","year":"2024","journal-title":"Front Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow\u2019s milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.jaci.2017.01.018","article-title":"Lifelong memory responses perpetuate humoral T(H)2 immunity and anaphylaxis in food allergy","volume":"140","author":"Jimenez-Saiz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01133-1","article-title":"The future of food allergy management: advancements in therapies","volume":"24","author":"Ezhuthachan","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaci.2009.05.022","article-title":"Clinical efficacy and immune regulation with peanut oral immunotherapy","volume":"124","author":"Jones","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","article-title":"Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective","volume":"139","author":"Vickery","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.007","article-title":"Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy","volume":"133","author":"Vickery","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.12.1037","article-title":"Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)","volume":"133","author":"Syed","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62301-6","article-title":"Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial","volume":"383","author":"Anagnostou","year":"2014","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1\u20133 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Investigators","year":"2018","journal-title":"New Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"EVIDoa2300145","DOI":"10.1056\/EVIDoa2300145","article-title":"Oral immunotherapy for peanut allergy in children 1 to less than 4 years of age","volume":"2","author":"Du Toit","year":"2023","journal-title":"NEJM Evid"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200435","article-title":"Oral immunotherapy for treatment of egg allergy in children","volume":"367","author":"Burks","year":"2012","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2011.10.023","article-title":"The safety and efficacy of sublingual and oral immunotherapy for milk allergy","volume":"129","author":"Keet","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(19)30029-X","article-title":"Walnut oral immunotherapy for desensitisation of walnut and additional tree nut allergies (Nut CRACKER): a single-centre, prospective cohort study","volume":"3","author":"Elizur","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/all.15212","article-title":"Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study)","volume":"77","author":"Elizur","year":"2022","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e085811","DOI":"10.1136\/bmjopen-2024-085811","article-title":"Efficacy and safety of low-dose sesame oral immunotherapy in paediatric patients: a protocol for a single-centre, randomised controlled trial","volume":"14","author":"Zielinska","year":"2024","journal-title":"BMJ Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jaci.2018.08.041","article-title":"Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy","volume":"143","author":"Nowak-W\u0119grzyn","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial","volume":"321","author":"Fleischer","year":"2019","journal-title":"Jama"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212895","article-title":"Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy","volume":"388","author":"Greenhawt","year":"2023","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.02.004","article-title":"Efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers: open-label extension to EPITOPE","volume":"13","author":"Greenhawt","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.02.029","article-title":"Cow\u2019s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity","volume":"125","author":"Dupont","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/all.14605","article-title":"Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis","volume":"76","author":"Pelletier","year":"2021","journal-title":"Allergy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jaci.2010.04.039","article-title":"Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties","volume":"126","author":"Allam","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1365-2222.2010.03462.x","article-title":"Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells","volume":"40","author":"Scadding","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.08.027","article-title":"Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract","volume":"116","author":"Enrique","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jaci.2010.12.1083","article-title":"Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization","volume":"127","author":"Kim","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jaci.2019.07.030","article-title":"Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization","volume":"144","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaci.2012.11.011","article-title":"Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial","volume":"131","author":"Fleischer","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.jaci.2023.01.036","article-title":"Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children","volume":"151","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.iac.2019.09.006","article-title":"Evolution of immune responses in food immunotherapy","volume":"40","author":"Smeekens","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"B50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11882-019-0894-y","article-title":"Biomarkers in food allergy immunotherapy","volume":"19","author":"Hardy","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2500\/jfa.2023.5.230002","article-title":"Mechanisms of desensitization with oral immunotherapy and epicutaneous immunotherapy","volume":"5","author":"Bellanti","year":"2023","journal-title":"J Food Allergy"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.979","article-title":"Immune mechanisms of oral immunotherapy","volume":"141","author":"Kulis","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2023.03.020","article-title":"Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy","volume":"152","author":"Calise","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/all.15276","article-title":"Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses","volume":"77","author":"Bajzik","year":"2022","journal-title":"Allergy"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.07.030","article-title":"Peanut-specific IgG4 and IgA in saliva are modulated by peanut oral immunotherapy","volume":"10","author":"Smeekens","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.11.045","article-title":"Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy","volume":"129","author":"Kulis","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.05.020","article-title":"Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy","volume":"150","author":"Kulis","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00006-2","article-title":"Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial","volume":"6","author":"Loke","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.anai.2023.04.023","article-title":"Treatment of food allergy: Oral immunotherapy, biologics, and beyond","volume":"131","author":"Sindher","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.anai.2022.12.031","article-title":"The epidemiology of multifood allergy in the United States: A population-based study","volume":"130","author":"Warren","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-022-01054-x","article-title":"Management of anaphylaxis during peanut oral immunotherapy","volume":"23","author":"Szafron","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cgh.2020.05.019","article-title":"Gastrointestinal eosinophil responses in a longitudinal, randomized trial of peanut oral immunotherapy","volume":"19","author":"Wright","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000688","article-title":"Eosinophilic esophagitis as a complication of food oral immunotherapy","volume":"20","author":"Jin","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.042","article-title":"Adverse reactions during peanut oral immunotherapy home dosing","volume":"124","author":"Varshney","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.01.030","article-title":"Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies","volume":"125","author":"Greenhawt","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jaip.2014.11.004","article-title":"Food allergies affect growth in children","volume":"3","author":"Hobbs","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B68","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jaci.2024.03.020","article-title":"Targeting inhibitory Siglec-3 to suppress IgE-mediated human basophil degranulation","volume":"154","author":"Barshow","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.614402","article-title":"Targeting the FcepsilonRI pathway as a potential strategy to prevent food-induced anaphylaxis","volume":"11","author":"Dispenza","year":"2020","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138448","article-title":"Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton\u2019s tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaci.2022.06.022","article-title":"Targeting CD22 on memory B cells to induce tolerance to peanut allergens","volume":"150","author":"Hardy","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2016.01.047","article-title":"Investigation of peanut oral immunotherapy with CpG\/peanut nanoparticles in a murine model of peanut allergy","volume":"138","author":"Srivastava","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.08.010","article-title":"Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals","volume":"155","author":"Layhadi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/all.15704","article-title":"The next generation virus-like particle platform for the treatment of peanut allergy","volume":"78","author":"Sobczak","year":"2023","journal-title":"Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1617153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:10:45Z","timestamp":1753157445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1617153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2025.1617153"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1617153","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1617153"}}